Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study

BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Ko...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Byeong Wook, Kim, Seok Bae, Song, Il Han, Lee, Sae Hwan, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Kim, Seok Hyun, Lee, Byung Seok, Chae, Hee Bok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381834/
https://www.ncbi.nlm.nih.gov/pubmed/28297836
http://dx.doi.org/10.3350/cmh.2016.0053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381834/
https://www.ncbi.nlm.nih.gov/pubmed/28297836
http://dx.doi.org/10.3350/cmh.2016.0053

Ejemplares similares